What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will the industry target its efforts? Will the battles take place at the state level? KHN senior correspondent Jay Hancock discussed these issues on Facebook Live Wednesday.
For more in-depth conversations with KHN reporters, check out our Facebook video archive.
KHN’s coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.
Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact firstname.lastname@example.org.